Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of jCell in Retinitis Pigmentosa
NCT02320812Phase 2Completed
- Sponsor
- jCyte, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famzeretcel in retinitis pigmentosa (RP), sponsored by jCyte, Inc. Primary endpoint: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability at 12 months. Started Jun 2015; status: completed.
02
Drugs
famzeretcel
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT02320812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320812.